What are the key molecular mechanisms by which gut microbiome dysbiosis drives neuroinflammation, alpha-synuclein aggregation, and dopaminergic neurodegeneration in Parkinson's disease via the gut-brain axis, and which microbiome-targeting therapeutic strategies (FMT, probiotics, prebiotics, vagus nerve modulation) show the most promise for disease modification?
Landscape Summary: Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation, and Therapeutic Strategies is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.
Colonna, Sevlever, et al. (TREM2 biology)
Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation, and Therapeutic Strategies — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: